

## **Pharmacy Drug Policy Checklist**

POLICY NAME Opzelura (ruxolitinib) POLICY # 3121P

## Criteria

Coverage Criteria for Atopic Dermatitis		
1.1 Diagnosis of mild to moderate atopic dermatitis		
1.2 Age 12 years or older		
<ul> <li>1.3 Prescribed by or in consultation with a dermatologist (skin doctor), allergist (allergy doctor), or immunologist (immune system doctor)</li> </ul>		
<ul> <li>1.4 Documented trial and failure or contraindication to topical corticosteroids, OR</li> <li>Contraindication to topical steroids include: ? Treatment of sensitive areas (face, anogenital skin folds) ? Steroid induced atrophy ? Long-term uninterrupted use</li> </ul>	l,	
<ul> <li>1.5 Documented trial and failure or contraindication to a topical calcineurin inhibitor (Tacrolimus ointment or Elidel cream)</li> </ul>		
• Contraindication to topical calcineurin inhibitors include: ? Severely impaired skin barrier (Netherton Syndrome) ? Risk/Presence of malignancy		

Coverage Criteria for Nonsegmental Vitiligo		
	2.1 Diagnosis of nonsegmental vitiligo	
	2.2 Total affected BSA does not exceed 10%	
	2.3 Other causes of depigmentation (lightening of skin) have been ruled out	
	2.4 Age 12 years or older	
	2.5 Prescribed by or in consultation with a dermatologist (skin doctor)	
	<ul><li>2.6 Documented trial and failure, intolerance or contraindication to one of the following:</li><li>Phototherapy</li><li>Oral immunosuppressant</li></ul>	
	Topical corticosteroid or calcineurin inhibitor	